AGAndre Ghetti

Andre Ghetti

*This is an algorithmically generated author record based on publicly available information.

Andre Ghetti has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Gene selection for prediction of transcriptome signal based on a machine learning approach

    by Pietro Demurtas, Jacopo Bertozzi, Irene Di Silvestro, Kevin Carlin, Andre Ghetti, Brian Krause, Giovanni Perini, Ferdinando Zanchetta, Rita Fioresi

    Background: In recent years, RNA-seq technology has gained widespread use in diverse research and clinical applications. Alongside this expansion, machine learning techniques have enabled accurate reconstruction of full transcriptomic signals from a considerably reduced set of highly informative genes (e.g., S1500+). Results: We employ machine learning methods, specifically XGBoost (eXtreme Gradient Boosting) a decision tree approach, to perform RNA-seq and transcriptomic analyses across multiple tissues. Our goal is to identify a small subset of expressed genes that can capture the complete tissue-specific transcriptomic profile. Using public GTEx (Genotype Tissue Expression) data, we analyze each tissue separately and discover the key fact that taking into account just the top 500 genes per tissue (ranked by XGBoost feature importance) are sufficient to provide transcriptomic signatures that match the performance of state-of-the-art gene sets (e.g., S1500+). To further validate our approach, we apply it to neuronal tissues by comparing samples from individuals with neuropathic pain versus those without pain. In dorsal root ganglia (DRG) RNA-seq data from patients experiencing varying levels of pain, our method suggests EGR1 as a factor in radicular/neuropathic pain, thereby opening avenues on the development of therapies that may alleviate pain by targeting EGR1 pathway. Conclusions: We demonstrate how to train and apply the XGBoost algorithm to select a small gene set that can approximate the full transcriptomic signal with varying accuracy depending on tissue type, generally achieving performance comparable to S1500+ gene sets in GTEx data. This method focusses on one tissue at a time, a different list of genes is selected for each tissue and ranked according to the importance of each gene into the reconstruction of the transcriptomic signal. This ranking also aids in highlighting specific genes that may be critical in predicting tissue-specific pathologies.

  • Chronic linaclotide treatment reduces colitis-induced neuroplasticity and reverses persistent bladder dysfunction

    by Luke Grundy, Andrea M. Harrington, Joel Castro, Sonia Garcia-Caraballo, Annemie Deiteren, Jessica Maddern, Grigori Y. Rychkov, Pei Ge, Stefanie Peters, Robert Feil, et al.

    Irritable bowel syndrome (IBS) patients suffer from chronic abdominal pain and extraintestinal comorbidities, including overactive bladder (OAB) and interstitial cystitis/painful bladder syndrome (IC-PBS). Mechanistic understanding of the cause and time course of these comorbid symptoms is lacking, as are clinical treatments. Here, we report that colitis triggers hypersensitivity of colonic afferents, neuroplasticity of spinal cord circuits, and chronic abdominal pain, which persists after inflammation. Subsequently, and in the absence of bladder pathology, colonic hypersensitivity induces persistent hypersensitivity of bladder afferent pathways, resulting in bladder-voiding dysfunction, indicative of OAB/IC-PBS. Daily administration of linaclotide, a guanylate cyclase-C (GC-C) agonist that is restricted to and acts within the gastrointestinal tract, reverses colonic afferent hypersensitivity, reverses neuroplasticity-induced alterations in spinal circuitry, and alleviates chronic abdominal pain in mice. Intriguingly, daily linaclotide administration also reverses persistent bladder afferent hypersensitivity to mechanical and chemical stimuli and restores normal bladder voiding. Linaclotide itself does not inhibit bladder afferents, rather normalization of bladder function by daily linaclotide treatment occurs via indirect inhibition of bladder afferents via reduced nociceptive signaling from the colon. These data support the concepts that cross-organ sensitization underlies the development and maintenance of visceral comorbidities, while pharmaceutical treatments that inhibit colonic afferents may also improve urological symptoms through common sensory pathways.